DATA GRAPHICS | Data Byte
GSK licenses second ADC from China-based Hansoh in two months
The deals mark the eighth and ninth in past five years for programs targeting PD-L1 family members B7-H3, B7-H4
December 21, 2023 2:03 AM UTC
As Western companies increasingly seek innovative products in China, especially antibody-drug conjugates, GSK entered its second deal with Hansoh in two months, giving the pharma access to another ADC against a different B7 family member.
GSK plc (LSE:GSK; NYSE:GSK) said Wednesday that it licensed rights outside Mainland China, Hong Kong, Macau, and Taiwan to B7-H3 ADC HS-20093 for $185 million up front. Hansoh Pharmaceutical Group Co. Ltd. (HKEX:03692) is eligible for up to $1.53 billion in milestones, plus tiered royalties. ...